Patient demographics according to presence or absence of late gadolinium enhancement (LGE)
| All patients (n=184) | LGEpos (n=72) | LGEneg (n=112) | p Value* | |
| Age (years) | 51.55±1.1 | 53.3±1.7 | 50±1.5 | ns |
| BMI (kg/m2) | 25.64±0.28 | 25.5±0.4 | 25.7±0.4 | ns |
| Males | 138 (75) | 58 (81) | 80 (71) | ns |
| Familial DCM | 27 (14.7) | 8 (1) | 19 (1.7) | ns |
| Arterial hypertension | 71 (38.6) | 28 (39) | 43 (38.4) | ns |
| Diabetes | 22 (12) | 11 (15) | 11 (1) | ns |
| Atrial fibrillation | 23 (12.5) | 8 (1) | 15 (13.4) | ns |
| NYHA functional class | ||||
| I | 42 (22.8) | 13 (18) | 29 (25.9) | ns |
| II | 88 (47.8) | 30 (41.7) | 58 (51.8) | ns |
| III | 54 (29.4) | 29 (40.2) | 25 (22.3) | 0.03 |
| Heart failure medication | ||||
| ACEI | 149 (81) | 60 (83.3) | 89 (79.5) | ns |
| ATRB | 35 (19) | 17 (23.6) | 18 (16) | ns |
| β\ blockers | 159 (86.4) | 66 (91.7) | 93 (83) | ns |
| Spironolactone | 78 (42.4) | 39 (58.3) | 39 (34.8) | 0.01 |
| Other diuretic | 87 (47.3) | 42 (58.3) | 45 (40.2) | 0.02 |
| Digoxin | 34 (18.5) | 16 (22.2) | 18 (16.1) | ns |
| NT-proBNP (pg/ml) | 255 (114–1488) | 491 (228.5–2932) | 254 (92–800) | 0.001 |
Values are mean±SEM, number (%) or median (IQR).
↵* LGEpos vs LGEneg.
ACEI, angiotensin-converting enzyme inhibitor; ATRB, angiotensin receptor blocker; BMI, body mass index; DCM, dilated cardiomyopathy; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association.